100 related articles for article (PubMed ID: 18564620)
1. [Pharmacokinetic and pharmacodynamic features of palonosetron].
Genazzani AA; Billington RA
Tumori; 2008; 94(2):suppl 6-13. PubMed ID: 18564620
[No Abstract] [Full Text] [Related]
2. Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting.
Ruhlmann C; Herrstedt J
Expert Rev Anticancer Ther; 2010 Feb; 10(2):137-48. PubMed ID: 20131990
[TBL] [Abstract][Full Text] [Related]
3. [Palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in Italy: pharmacologic, clinical and economic aspects].
Pradelli L; Eandi M
Tumori; 2008; 94(2):suppl 26-32. PubMed ID: 18564623
[No Abstract] [Full Text] [Related]
4. Palonosetron (Aloxi) for prevention of nausea and vomiting due to cancer chemotherapy.
Med Lett Drugs Ther; 2004 Mar; 46(1179):27-8. PubMed ID: 15057189
[No Abstract] [Full Text] [Related]
5. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Rubenstein EB
Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacological, pharmacokinetic, and clinical profile of palonosetron hydrochloride (ALOXI I.V. Injection 0.75 mg), a novel antiemetic 5-HT3-receptor antagonist].
Ajioka H; Morita F; Akizawa Y; Yoshida K; Kitamura R; Takimoto H
Nihon Yakurigaku Zasshi; 2010 Aug; 136(2):113-20. PubMed ID: 20702972
[No Abstract] [Full Text] [Related]
7. Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels.
Kuryshev YA; Brown AM; Wang L; Benedict CR; Rampe D
J Pharmacol Exp Ther; 2000 Nov; 295(2):614-20. PubMed ID: 11046096
[TBL] [Abstract][Full Text] [Related]
8. 5-HT3-receptor antagonists and the cytochrome P450 system: clinical implications.
Blower PR
Cancer J; 2002; 8(5):405-14. PubMed ID: 12416899
[TBL] [Abstract][Full Text] [Related]
9. [Meta-analysis of phase III studies with palonosetron in the prevention of vomiting induced by moderately emetogenic chemotherapy].
Di Maio M; Gallo C; Perrone F
Tumori; 2008; 94(2):suppl 14-22. PubMed ID: 18564621
[No Abstract] [Full Text] [Related]
10. Relative efficacy of ondansetron, granisetron, dolasetron and palonosetron in controlling acute nausea and vomiting associated with platinum-based chemotherapy.
Hamadani M; Awab A; Chaudhary L; Tfayli A
J Oncol Pharm Pract; 2006 Jun; 12(2):67-8. PubMed ID: 16984743
[No Abstract] [Full Text] [Related]
11. Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function.
Rojas C; Thomas AG; Alt J; Stathis M; Zhang J; Rubenstein EB; Sebastiani S; Cantoreggi S; Slusher BS
Eur J Pharmacol; 2010 Jan; 626(2-3):193-9. PubMed ID: 19836386
[TBL] [Abstract][Full Text] [Related]
12. The activity of dihydropyrimidine dehydrogenase from rat liver was not affected by any of five 5-hydroxytryptamine antagonists.
Tateishi T; Nakura H; Watanabe M; Tanaka M; Kumai T; Kobayashi S
Cancer Lett; 1996 Nov; 108(1):1-5. PubMed ID: 8950202
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers.
Shah AK; Hunt TL; Gallagher SC; Cullen MT
Curr Med Res Opin; 2005 Apr; 21(4):595-601. PubMed ID: 15899109
[TBL] [Abstract][Full Text] [Related]
14. Prolonged inhibition of 5-HT₃ receptors by palonosetron results from surface receptor inhibition rather than inducing receptor internalization.
Hothersall JD; Moffat C; Connolly CN
Br J Pharmacol; 2013 Jul; 169(6):1252-62. PubMed ID: 23581504
[TBL] [Abstract][Full Text] [Related]
15. Interaction of the antiemetics ondansetron and granisetron with the cytotoxicity induced by irradiation, epirubicin, bleomycin, estramustine, and cisplatin in vitro.
Behnam Motlagh P; Henriksson R; Grankvist K
Acta Oncol; 1995; 34(6):871-5. PubMed ID: 7576757
[TBL] [Abstract][Full Text] [Related]
16. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
Eisenberg P; Figueroa-Vadillo J; Zamora R; Charu V; Hajdenberg J; Cartmell A; Macciocchi A; Grunberg S;
Cancer; 2003 Dec; 98(11):2473-82. PubMed ID: 14635083
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of palonosetron in postoperative nausea and vomiting (PONV)-a meta-analysis.
Singh PM; Borle A; Gouda D; Makkar JK; Arora MK; Trikha A; Sinha A; Goudra B
J Clin Anesth; 2016 Nov; 34():459-82. PubMed ID: 27687434
[TBL] [Abstract][Full Text] [Related]
18. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer.
Navari RM
Future Oncol; 2010 Jul; 6(7):1073-84. PubMed ID: 20624119
[TBL] [Abstract][Full Text] [Related]
19. [From cocaine to innovative antiemetics. The medicinal chemistry of 5-ht3 receptor antagonists].
Zettl H; Schubert-Zsilavecz M; Siebert CD
Pharm Unserer Zeit; 2007; 36(5):354-61. PubMed ID: 17722162
[No Abstract] [Full Text] [Related]
20. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists.
Navari RM; Koeller JM
Ann Pharmacother; 2003 Sep; 37(9):1276-86. PubMed ID: 12921512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
